Dylan F. Conklin, Ph.D.

Affiliations: 
2013 Epidemiology University of California, Los Angeles, Los Angeles, CA 
Area:
Oncology, Epidemiology
Google:
"Dylan Conklin"

Parents

Sign in to add mentor
Zuo-Feng Zhang grad student 2013 UCLA
 (Identification of Genomic Predictors of Response to the CDK4/6 Inhibitor Palbociclib using the UCLATORL Panel of Human Cancer Cell Lines.)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

O'Brien NA, McDermott MSJ, Conklin D, et al. (2020) Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast Cancer Research : Bcr. 22: 89
McDermott MS, Conklin DF, O'Brien NA, et al. (2020) Abstract P2-05-07: Pan-cancer analysis of PARP inhibition reveals a suite of biomarkers that correlate with PARP1/2 activity in breast cancer Cancer Research. 80
O'Brien N, Conklin D, McDermott M, et al. (2019) Abstract P6-17-11: The small molecule inhibitor of HER2, tucatinib, has potent and highly selective activity in preclinical modes of HER2-driven cancer Cancer Research. 79
O'Brien NA, McDermott MS, Conklin DF, et al. (2019) Abstract 3825: Targeting activated PI3K/mTOR signaling overcomes resistance to CDK4/6-based therapies in preclinical ER+ breast cancer models Cancer Research. 79: 3825-3825
Papp E, Hallberg D, Konecny GE, et al. (2018) Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. Cell Reports. 25: 2617-2633
O'Brien N, Conklin D, Beckmann R, et al. (2018) Preclinical activity of abemaciclib alone or in combination with anti-mitotic and targeted therapies in breast cancer. Molecular Cancer Therapeutics
Fejzo MS, Anderson L, Chen HW, et al. (2017) Proteasome Ubiquitin Receptor PSMD4 is an Amplification Target in Breast Cancer and May Predict Sensitivity to PARPi. Genes, Chromosomes & Cancer
Li J, Zhao W, Akbani R, et al. (2017) Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell. 31: 225-239
O'Brien NA, Conklin D, Luo T, et al. (2017) Abstract 4150: Anti-tumor activity of the PI3K/mTOR pathway inhibitors alpelisib (BYL719) and everolimus (RAD001) in xenograft models of acquired resistance to CDK-4/6 targeted therapy Cancer Research. 77: 4150-4150
Larson SM, Peng MY, Vandross A, et al. (2016) Activity of the Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Copanlisib, As a Single Agent and in Combination with Carfilzomib in Multiple Myeloma Blood. 128: 5665-5665
See more...